Skip to main content

Table 2 Age-standardised two-year mortality rates among men with newly managed prostate cancer (PCa) in 2009 according to treatment, and frequency of treatments and their combinations among men still alive at two-years according to age

From: Prostate cancer outcomes in France: treatments, adverse effects and two-year mortality

  Death rate Frequency of treatment
  Age-standardised 40-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 ≥85 Total
N 43,460 414 1,433 3,727 6,782 6,792 7,033 5,554 3,106 1,893 36,734
Treatments (at least one) % % % % % % % % % % %
Total prostatectomy 4.3 46.9 66.9 65.8 60.6 54.2 32.4 6.0 0.2 0.3 38.1
- laparoscopy 3.5 20.3 37.7 36.6 33.2 30.9 19.7 3.8 0.1 0.2 21.6
- laparotomy 5.1 26.6 29.2 29.2 27.4 23.3 12.7 2.1 0.1 0.1 16.5
Hormone therapy 9.4 40.3 21.4 20.3 20.5 25.4 34.9 53.3 65.4 66.8 35.5
Subcapsular orchidectomy 12.7 1.2 0.3 0.2 0.1 0.1 0.2 0.4 1.2 1.3 0.3
Chemotherapy 38.5 4.3 2.5 1.6 1.6 1.4 1.5 1.7 1.8 1.1 1.6
Brachytherapy 0.8 2.4 3.0 4.2 4.0 2.8 2.7 1.2 0.1 0.0 2.5
External beam radiotherapy 14.0 18.4 21.1 24.8 26.0 28.8 39.7 40.6 12.2 3.5 28.6
No treatment*: 13.6 12.1 13.9 14.7 16.9 17.8 20.7 24.6 30.2 31.2 20.4
- Hospitalisation with PCa diagnosis 15.0 10.4 11.0 11.5 12.8 13.6 15.3 17.9 22.9 25.5 15.5
- Isolated LTCD for PCa 8.1 1.7 2.9 3.2 4.2 4.2 5.3 6.7 7.2 5.7 4.9
Treatment combinations % % % % % % % % % % %
Prostatectomy, all types            
Alone 4.4 37.4 53.5 52.3 49.4 43.7 25.4 4.8 0.2 0.1 30.6
Combined with:            
- Hormone therapy 1.2 1.9 3.6 3.4 2.8 3.0 2.1 0.6 0.0 0.1 2.1
- External beam radiotherapy 4.2 4.1 5.7 5.6 5.0 4.1 2.8 0.4 0.0 0.0 3.1
- External beam radiotherapy 0.4 2.9 4.0 4.1 3.2 3.2 1.9 0.3 0.0 0.0 2.2
+ Hormone therapy
Hormone therapy            
Alone 9.5 28.3 6.8 4.0 3.8 5.6 9.8 26.4 55.9 64.0 16.6
Combined with:            
- External beam radiotherapy 8.9 4.3 4.9 6.7 8.7 11.6 19.1 23.9 8.5 2.5 12.8
External beam radiotherapy alone 30.0 2.2 2.5 3.4 4.7 6.7 12.9 14.3 3.0 0.7 7.5
  1. LTCD: long term chronic disease status.
  2. *Absence of the above treatments during the two-year follow-up.